NCT06953999 - A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

999

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

May 14, 2027

Study Completion Date

May 14, 2028

Conditions

Pancreatic Cancer

Interventions

DRUG

Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine

"Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV).~AK117: a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."

DRUG

Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine

"Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV).~AK117 Placebo: a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."

DRUG

Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine

"Ivonescimab Placebo : a specified dose and frequency administrated by intravenous infusion (IV).~AK117 Placebo : a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."

Trial Locations (2)

20032

Fudan University Shanghai Cancer Center, Shanghai

310022

Zhejiang Cancer Hospital, Hangzhou